ReportWire

Tag: molecular biology

  • Scientists Gather to Confront the Doomsday Risks of ‘Mirror Life’

    [ad_1]

    The prospect of creating “mirror life”—synthetic cells made from molecules that are mirror images of those found in nature—remains completely hypothetical. Still, the potential consequences are so dire that experts from around the world are gathering to discuss how to prevent the worst-case scenario.

    This week, scientists, engineers, policymakers, and other stakeholders will convene in Manchester, U.K., for Engineering and Safeguarding Synthetic Life 2025. This annual international conference explores the risks, challenges, and opportunities in researching and building synthetic life. Mirror life is emerging as a topic worthy of substantial discussion, as many scientists warn that creating such cells could pose unprecedented and irreversible risks to human health and the environment.

    “Pretty much everybody agrees” that mirror-image cells would be “a bad thing,” John Glass, a synthetic biologist at the J. Craig Venter Institute, told Nature. At the same time, some scientists argue that mirror-life research offers potential benefits that shouldn’t be ignored. The question is: How should experts regulate such research to maximize those benefits while minimizing risk?

    Why study mirror life?

    Most biological molecules that make up life on Earth—including all proteins, DNA, and RNA—point either left or right. These molecules are “chiral,” meaning they cannot be superimposed on their mirror image. Just as your right glove only fits on your right hand, chiral molecules can only interact with other molecules of compatible chirality.

    Mirror-image cells would be built from synthetic molecules with the opposite chirality of those found in nature. Whereas DNA is right-handed, mirror DNA would be left-handed, for example. Scientists are still decades away from synthesizing a complete mirror-image cell, but in recent years, they have created some mirror-image biomolecules, such as chirally inverted enzymes that can replicate and transcribe mirror-image DNA and RNA.

    One of the main incentives for creating mirror-image cells is that they could help scientists unravel how chirality emerged in nature, but the building blocks for these cells also hold promise for bioengineering and therapeutic drug discovery. Researchers believe the body’s enzymes and immune system would not readily recognize mirror-image biomolecules, allowing medicines made from them to remain more stable in the bloodstream. The FDA has already approved one such drug to treat chronic kidney disease.

    What are the risks?

    Even these early advancements worry some scientists. The same properties that make these synthetic biomolecules effective as therapeutics would likely allow mirror-image cells to spread uncontrollably throughout the body or nature.

    With the ability to evade immune systems, medicines, predation, and viral infection, experts have warned that mirror-image bacteria could gradually take over the environment. Scientists can only theorize about the consequences of this worst-case scenario, but there is strong evidence to suggest that mirror-image bacteria could catastrophically destabilize the environment and pose significant risks to human health.

    Some believe these risks warrant abandoning the prospect of creating mirror life. Others argue that well-placed restrictions and guidelines could allow research to progress without posing a threat to life as we know it. The question of how to move forward—if at all—will likely stir up a spirited debate at this week’s conference in Manchester.

    [ad_2]

    Ellyn Lapointe

    Source link

  • BioSpyder Awarded 5-Year EPA Contract With a Maximum Value of $25 Million to Perform High-Throughput Genetic Toxicology Screening

    BioSpyder Awarded 5-Year EPA Contract With a Maximum Value of $25 Million to Perform High-Throughput Genetic Toxicology Screening

    [ad_1]

    Faster, Cheaper, Better – TempO-Seq® Assay Establishes Itself as a Leading Gene Expression Profiling Tool

    Press Release



    updated: Jul 1, 2020

    ​​​​BioSpyder Technologies, Inc. has been awarded the contract to perform High Throughput Toxicology Screening by the United States Environmental Protection Agency (EPA) Center for Computational Toxicology and Exposure (CCTE). Since 2015, the EPA’s HHT Research Program has contracted with BioSpyder to perform toxicology screening using the BioSpyder TempO-Seq® assay. This new contract is a significant increase over prior contracts, reflecting the EPA’s commitment to using new approach methods to evaluate chemicals and a high level of satisfaction with BioSpyder’s TempO-Seq® assay.

    The EPA’s CCTE coordinates the High Throughput Toxicology (HTT) Research Program, which is part of the EPA’s broader Chemical Safety for Sustainability Strategic Research Action Plan. A major part of the EPA’s HTT research is the Toxicity Forecaster (ToxCast™). ToxCast is a multi-year effort launched in 2007 that uses high-throughput methods to expose living cells or isolated proteins to chemicals. The cells or proteins are then screened for changes in biological activity that may be indicative of potential toxic effects and eventually potential adverse health effects. The BioSpyder TempO-Seq® assay has proven to be highly efficient and cost-effective in screening the hundreds of thousands of samples that are being generated.

    “Interest in high-throughput molecular testing has peaked due to SARS CoV-2, so the awarding of this contract is timely validation of our TempO-Seq® assay,” said Joel McComb, BioSpyder CEO. “We thank the EPA CCTE team for being instrumental in helping establish BioSpyder and our TempO-Seq assay as a leader in genetic toxicology screening.”

    The team at EPA CCTE grows cells and lyse in TempO-Seq buffer, then ships them to BioSpyder in multi-well plate format. No purification step is required, saving cost and removing purification bias. BioSpyder assays the samples through multiplexed Tempo-Seq assays that measure transcriptomic changes for up to 21,000 protein coding genes directly on the cell lysates provided. Following sequencing, results including gene counts, QC metrics, and sequencing files are securely transferred to the EPA for analysis.

    BioSpyder has been awarded by the U.S. Environmental Protection Agency Computational Toxicology a five-year contract that has a maximum total contract value of USD 25 million. This contract is the latest in a series of contracts awarded to BioSpyder from the EPA for HTT research since 2015. Two other contracts were awarded to BioSpyder by this organization, one for $5 million and the other for $10 million, and have been fully utilized and successfully fulfilled.

    About the TempO-Seq® Assay

    TempO-Seq® is a molecular profiling tool that allows for targeted gene expression analysis, designed to monitor hundreds to thousands of genes at once in high throughput. TempO-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. TempO-Seq has critical usability features, controls, and does not require specialized instrumentation.

    In addition to saving costs in RNA purification, the targeted nature of TempO-Seq® allows for extremely efficient and cost-effective sequencing. An automated probe design process allows users to target only genes of interest and TempO-Seq maximizes sequencing efficiency by sequencing only unique targets, not entire genes. Samples are pooled into libraries as large as 384 samples, which gives users the versatility to ensure samples receive the appropriate number of reads.

    About BioSpyder Technologies, Inc.

    BioSpyder is based in Carlsbad, California, and is a privately held company largely funded by government grants. BioSpyder is the developer of TempO-Seq®. Through its U.K. (Glasgow) subsidiary BioClavis, BioSpyder is providing personalized diagnostics services. BioClavis leverages the BioSpyder TempO-Seq® platform technology for precision diagnostics and drug discovery. BioSpyder Technologies was founded in 2011 by veteran molecular biology executives Joel McComb, Joanne Yeakley, Ph.D., and Bruce Seligmann, Ph.D. More information about BioSpyder Technologies is available at www.biospyder.com.

    Media Contact: PublicRelations@biospyder.com

    Source: BioSpyder Technologies, Inc.

    [ad_2]

    Source link